Therapeutic Drug Monitoring of Lithium Carbonate
... adults aged 18-80 years receiving multiple daily doses of lithium carbonate for, at least, 7 consecutive days prior to the commencement of the study. The patients were included if they had no evidence of cardiac, respiratory, hepatic or renal abnormalities. Patients who were on sodium-restricted die ...
... adults aged 18-80 years receiving multiple daily doses of lithium carbonate for, at least, 7 consecutive days prior to the commencement of the study. The patients were included if they had no evidence of cardiac, respiratory, hepatic or renal abnormalities. Patients who were on sodium-restricted die ...
GnRH-Gemcitabine Conjugates for the Treatment ... Independent Prostate Cancer: Pharmacokinetic Enhancements
... cell responses to either agonist or antagonist drugs of the receptor.14 It is also well established that GnRH-R gene expression is upregulated in patients with androgenindependent CaP, making the GnRH-R an attractive target for the design of novel and specific therapeutics.15 A modern approach to im ...
... cell responses to either agonist or antagonist drugs of the receptor.14 It is also well established that GnRH-R gene expression is upregulated in patients with androgenindependent CaP, making the GnRH-R an attractive target for the design of novel and specific therapeutics.15 A modern approach to im ...
Octreotide Acetate Injection in a prefilled syringe
... of patients. In acromegalic patients, diarrhea, loose stools, nausea and abdominal discomfort were each seen in 34% to 61% of patients, although only 2.6% of patients discontinued due to these symptoms. These symptoms were seen in 5% to 10% of patients with other disorders. Hypoglycemia and hypergly ...
... of patients. In acromegalic patients, diarrhea, loose stools, nausea and abdominal discomfort were each seen in 34% to 61% of patients, although only 2.6% of patients discontinued due to these symptoms. These symptoms were seen in 5% to 10% of patients with other disorders. Hypoglycemia and hypergly ...
Felbamate (PDF, 63KB, File is accessible)
... Adjunctive therapy with other antiepileptic agents : /.../felbamate administered in combination with carbamazepine, phenytoin, phenobarbital or valproic acid may increase the incidence of their characteristic adverse reactions (see section 4.5). Initiate /.../felbamate dosage at 600 mg to 1200 mg/da ...
... Adjunctive therapy with other antiepileptic agents : /.../felbamate administered in combination with carbamazepine, phenytoin, phenobarbital or valproic acid may increase the incidence of their characteristic adverse reactions (see section 4.5). Initiate /.../felbamate dosage at 600 mg to 1200 mg/da ...
Diminished Cocaine-Like Effects in Dopamine Transporter Ligands
... was started with the addition of the tissue, and the tubes were incubated for 60 min in a 371°C water bath. The incubation was terminated by the addition of 5 ml of ice-cold buffer (10 mM Tris-HCl, pH 7.4) and rapid filtration through Whatman GF/B glass fiber filter paper (presoaked in 0.5% polyethy ...
... was started with the addition of the tissue, and the tubes were incubated for 60 min in a 371°C water bath. The incubation was terminated by the addition of 5 ml of ice-cold buffer (10 mM Tris-HCl, pH 7.4) and rapid filtration through Whatman GF/B glass fiber filter paper (presoaked in 0.5% polyethy ...
vancomycin 500mg and 1000mg powder for concentrate for solution
... Concentrations of no more than 5mg/ml are recommended. In selected patients in need of fluid restriction, a concentration up to 10mg/ml may be used; use of such higher concentrations may increase the risk of infusion-related events. Infusions should be given over at least 60 minutes. In adults, if d ...
... Concentrations of no more than 5mg/ml are recommended. In selected patients in need of fluid restriction, a concentration up to 10mg/ml may be used; use of such higher concentrations may increase the risk of infusion-related events. Infusions should be given over at least 60 minutes. In adults, if d ...
Revealing the secrets - Canadian Healthcare Network
... t’s time to lay to rest any hope that Ginkgo biloba will prevent Alzheimer’s disease and cognitive impairment. That was the opinion of Dr. Lon Schneider, the director of the University of Southern California’s Alzheimer’s Disease Research Center in Los Angeles, on the latest major clinical trial on ...
... t’s time to lay to rest any hope that Ginkgo biloba will prevent Alzheimer’s disease and cognitive impairment. That was the opinion of Dr. Lon Schneider, the director of the University of Southern California’s Alzheimer’s Disease Research Center in Los Angeles, on the latest major clinical trial on ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... mg/ kg, We hypothesised that 2mcg/kg produces more satisfactory sedation when compared to 1mcg/kg based on previous studies10.The discrepancy between our results and theirs may be attributed to pharmacokinetic factors15,16 including different age groups, children characteristics, and dissimilar seda ...
... mg/ kg, We hypothesised that 2mcg/kg produces more satisfactory sedation when compared to 1mcg/kg based on previous studies10.The discrepancy between our results and theirs may be attributed to pharmacokinetic factors15,16 including different age groups, children characteristics, and dissimilar seda ...
Steady-state bioequivalence studies of two memantine tablet and
... No. 19091G-113). The operating temperature for the injector and detector was 280 °C. The oven temperature was programmed as follows: 1 min interval at 143 °C, 50 °C/min up to 193 °C, then 4 °C/min up to 221 °C, then 40 °C/min up to 240 °C and held for 2.45 min. An equilibration period of 2 min was s ...
... No. 19091G-113). The operating temperature for the injector and detector was 280 °C. The oven temperature was programmed as follows: 1 min interval at 143 °C, 50 °C/min up to 193 °C, then 4 °C/min up to 221 °C, then 40 °C/min up to 240 °C and held for 2.45 min. An equilibration period of 2 min was s ...
What is the difference between the buccal midazolam preparations
... Epistatus® 10mg/ml buccal liquid contains midazolam maleate and is an unlicensed product in Ireland. It is not currently available on the medical card (GMS) or Drug Payment Schemes (DPS). Epistatus is supplied as 5mls of liquid in a 30ml bottle. Buccolam® oromucosal solution contains midazolam hydro ...
... Epistatus® 10mg/ml buccal liquid contains midazolam maleate and is an unlicensed product in Ireland. It is not currently available on the medical card (GMS) or Drug Payment Schemes (DPS). Epistatus is supplied as 5mls of liquid in a 30ml bottle. Buccolam® oromucosal solution contains midazolam hydro ...
Update on the Pharmacodynamics and
... 20 pg/ml, it is acknowledged not with adequate safety. serum ...
... 20 pg/ml, it is acknowledged not with adequate safety. serum ...
About the Futile Dream of an Entirely Riskless and Fully
... Grünenthal, as the official version has it) seemed to be pharmacologically the most interesting one. However, none of the other substances are discussed in that paper (and have not been discussed since). K 17 is described as a white solid with a melting point of 271 °C. The solubility is severely re ...
... Grünenthal, as the official version has it) seemed to be pharmacologically the most interesting one. However, none of the other substances are discussed in that paper (and have not been discussed since). K 17 is described as a white solid with a melting point of 271 °C. The solubility is severely re ...
Ibuprofen and paracetamol for patent ductus arteriosus
... treatment and its possible failure in closing PDA makes welcome an alternative pharmacological treatment. In fact, the recent publication of caseseries reporting on the effectiveness of paracetamol in closing PDA is very interesting. Non-steroidal anti-inflammatory drugs are known to facilitate duct ...
... treatment and its possible failure in closing PDA makes welcome an alternative pharmacological treatment. In fact, the recent publication of caseseries reporting on the effectiveness of paracetamol in closing PDA is very interesting. Non-steroidal anti-inflammatory drugs are known to facilitate duct ...
Chronic Metabolic Acidosis Increases the Serum Concentration of 1
... from bone ( 1 ) in association with hypercalciuria. Important clinical sequelae are a metabolic bone disease resembling osteomalacia (2-8) and calcium nephrolithiasis (9). Reduced serum concentrations of the active metabolite of vitamin D, 1,25-(OH)2D, have been implicated in mediating the acidosis- ...
... from bone ( 1 ) in association with hypercalciuria. Important clinical sequelae are a metabolic bone disease resembling osteomalacia (2-8) and calcium nephrolithiasis (9). Reduced serum concentrations of the active metabolite of vitamin D, 1,25-(OH)2D, have been implicated in mediating the acidosis- ...
Product Monograph
... Effect on Lipoprotein(a): In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by a concomitant increase in the Lipoprotein(a) [Lp(a)] level. Further research is currently ongoing to elucidate the significance of Lp(a) plasma level variations. T ...
... Effect on Lipoprotein(a): In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by a concomitant increase in the Lipoprotein(a) [Lp(a)] level. Further research is currently ongoing to elucidate the significance of Lp(a) plasma level variations. T ...
Clinical Pharmacology of Boceprevir (BOC): Metabolism
... o Effect of CYP3A4 inhibitors & inducers modest o Drugs affecting other enzymes/transporters unlikely to alter boceprevir o No dose adjustments of boceprevir required ...
... o Effect of CYP3A4 inhibitors & inducers modest o Drugs affecting other enzymes/transporters unlikely to alter boceprevir o No dose adjustments of boceprevir required ...
EFFECT OF VALERIAN ROOT EXTRACTS (VALERIANA
... extracts were investigated in a study in healthy human volunteers. Valerian ...
... extracts were investigated in a study in healthy human volunteers. Valerian ...
SCIENTIFIC DISCUSSION 1. Introduction Fungal infections have
... Posaconazole, like other azoles, inhibits the enzyme lanosterol 14α-demethylase that is necessary for ergosterol biosynthesis in yeasts and filamentous fungi. This enzyme is also known as CYP51A or Erg11p and is encoded by the ERG11 gene. In-vitro studies showed a direct correlation between the abil ...
... Posaconazole, like other azoles, inhibits the enzyme lanosterol 14α-demethylase that is necessary for ergosterol biosynthesis in yeasts and filamentous fungi. This enzyme is also known as CYP51A or Erg11p and is encoded by the ERG11 gene. In-vitro studies showed a direct correlation between the abil ...
PUBLIC ASSESSMENT REPORT Decentralised Procedure
... Gp IIb/IIIa receptor activation. Clopidogrel is a thienopyridine and only the S-enantiomer is pharmacologically active. Clopidogrel is indicated for the prevention of atherothrombotic events in: ...
... Gp IIb/IIIa receptor activation. Clopidogrel is a thienopyridine and only the S-enantiomer is pharmacologically active. Clopidogrel is indicated for the prevention of atherothrombotic events in: ...
NEW ZEALAND DATA SHEET 1. PRODUCT NAME 2
... concomitant medication with amiodarone (see Dose and method of administration; Interaction with other medicines and other forms of interaction). Verapamil or dilitazem: In a pharmacokinetic study, co-administration of diltiazem and simvastatin resulted in a mean 70% increase in systemic exposure to ...
... concomitant medication with amiodarone (see Dose and method of administration; Interaction with other medicines and other forms of interaction). Verapamil or dilitazem: In a pharmacokinetic study, co-administration of diltiazem and simvastatin resulted in a mean 70% increase in systemic exposure to ...
Package Insert
... The risk of myopathy during treatment with rosuvastatin may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir [see Dosage and Administration (2) and Drug Interac ...
... The risk of myopathy during treatment with rosuvastatin may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir [see Dosage and Administration (2) and Drug Interac ...
PREZISTA® (darunavir) oral suspension PREZISTA® (darunavir
... Prescribers should select the appropriate dose of PREZISTA/ritonavir for each individual child based on body weight (kg) and should not exceed the recommended dose for adults. Before prescribing PREZISTA, children weighing greater than or equal to 15 kg should be assessed for the ability to swallow ...
... Prescribers should select the appropriate dose of PREZISTA/ritonavir for each individual child based on body weight (kg) and should not exceed the recommended dose for adults. Before prescribing PREZISTA, children weighing greater than or equal to 15 kg should be assessed for the ability to swallow ...
Effect of St John`s Wort on Drug Metabolism by Induction of
... major St John’s wort constituents in plasma, but limited pharmacokinetic data are available from other studies.45,46 The major constituents of the St John’s wort product used in this study were documented. This is essential when performing clinical studies with herbal products because substantial va ...
... major St John’s wort constituents in plasma, but limited pharmacokinetic data are available from other studies.45,46 The major constituents of the St John’s wort product used in this study were documented. This is essential when performing clinical studies with herbal products because substantial va ...
Full Prescribing Information for GONAL-F® RFF
... suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy, have been reported in association with OHSS. OHSS occurs after gonadotropin treatment has been discontinued and it can develop rapidly, reaching its maximum about seven to ten days following treatment. Usually, OH ...
... suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy, have been reported in association with OHSS. OHSS occurs after gonadotropin treatment has been discontinued and it can develop rapidly, reaching its maximum about seven to ten days following treatment. Usually, OH ...
Effect of Surface Chemistry on the Immune Responses and Cellular
... therapeutic applications due to their easily modifiable surface, large pore volumes, high surface area, nontoxic nature, and high biocompatibility. Nevertheless, there is no comprehensive understanding about the role of the surface chemistry of these NPs on the biological interactions and the therap ...
... therapeutic applications due to their easily modifiable surface, large pore volumes, high surface area, nontoxic nature, and high biocompatibility. Nevertheless, there is no comprehensive understanding about the role of the surface chemistry of these NPs on the biological interactions and the therap ...